Biotie Therapies - Annual Financial Report

Biotie's Annual Financial Report 2008 published

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE    March 27, 2009 at
8.35 a.m.


Biotie's Annual Financial Report 2008 published

Biotie Therapies Corp.'s Annual financial report for 2008 has been
published. The report is avalailable as PDF file on Biotie's website
at www.biotie.com in English and Finnish language.

Biotie's Annual Report for 2008 will be published during week 18,
starting on April 27, 2009.


Turku, March 27, 2009

Biotie Therapies Corp.


Timo Veromaa
President and CEO


For further information, please contact:

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media

Appendix:
Biotie Therapies Corp. Annual Financial Report 2008

Biotie Therapies Corp.
Biotie is a drug discovery and development company focused on central
nervous system and inflammatory diseases. It has a broad range of
innovative small molecule and biological drug candidates at different
stages of clinical and pre-clinical development. Biotie's products
address diseases with high unmet medical need and significant market
potential, including addiction and psychotic disorders, rheumatoid
arthritis, psoriasis and chronic obstructive pulmonary disease
(COPD). The most advanced product, nalmefene for alcohol dependence,
is currently in phase III clinical development by licensing partner
H. Lundbeck A/S.

The commercial value of the pipeline has been demonstrated through
existing alliances with top-tier global pharmaceutical companies such
as Lundbeck, Roche and Wyeth. Biotie has operations in Turku, Finland
and Radebeul, Germany.

Attachments:

Biotie Annual Financial Report 2008.pdf